VolitionRx (NYSE American: VNRX) has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co. in Japan, allowing use of full automation rather than manual plates in central laboratories.
In a statement, Junichi Makino, president and representative director at Fujifilm Vet Systems, commented, “We are excited to be the first in the world to utilize this centralized lab automation for the Nu.Q Vet Cancer Test, this is a big step forward from the current use of manual plates. Since our launch of the Nu.Q Vet Cancer Test in July 2024, there has been an incredible amount of interest amongst Japanese veterinarians, indeed the number of veterinary hospitals registered to use the test in Japan already exceeds 1,700. This automated test will enable a more rapid turnaround and high throughput to meet increasing demand.”
Dr. Jasmine Kway, CEO of Singapore Volition added, “There are approximately seven million pet dogs in Japan. Given Fujifilm Vet Systems is a leading provider of diagnostic tests in this large market, it presents an exciting revenue opportunity for Volition. Cancer is the leading cause of adult canine deaths and earlier detection can improve outcomes. The Nu.Q Vet Cancer Test is an accessible and affordable screening tool for dogs to aid in early cancer detection. This automated test via the Immunodiagnostic Systems (IDS) i10 automated analyzer platform is the same platform Volition utilizes for its human products: Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover, demonstrating the synergy across not only the Nu.Q technology platform but also between humans and dogs.”
